Note: Descriptions are shown in the official language in which they were submitted.
CA 02774495 2016-03-29
IMPLANT DEVICES THAT DIFFER BY RELEASE PROFILE AND METHODS
OF MAKING AND USING SAME
BACKGROUND
Implant formulations can be designed to release bioactive agents into a fluid
or
tissue of a subject. Useful formulations are those that comprise a polymer
that releases the
bioactive agent as the polymer biodegrades. One purpose of the polymer is to
restrict the
influx of water, which in turns controls the dissolution of the bioactive
agent followed by
the release of the bioactive agent from the implant. While the polymer
provides a number
of advantages, such as restricting water influx, it can be difficult to
provide an appropriate
polymer formulation that is effective to achieve a targeted or effective
release profile. A
variety of different release profiles are needed in the pharmaceutical arts
that generally
depend on variables in the subject to be treated and the particular
characteristics of the
disorder. Unfortunately, a typical drug-delivery strategy based on a single
implant
composition often fails to meet the needs of varying release profiles.
As such, a need exists for drug-delivery strategies that can effectively
provide for a
desired release profile without undue manufacturing limitations. These needs
and other
needs are satisfied by the present invention.
SUMMARY
Described herein are implant devices, kits comprising the implant devices, and
methods of making and using the devices and kits. In one aspect, a plurality
implant
devices comprises at least two implants that exhibit a different release
profile of a bioactive
agent. In another aspect, an implant device comprises one or more adjoined
polymer
bodies, wherein at least two of the polymer bodies provide a different release
profile of a
bioactive agent. In another aspect, a kit comprises one or more disclosed
implant devices.
In another aspect, methods of delivering a bioactive agent to a subject
comprise
administering to the subject one or more disclosed implant devices.
The advantages of the invention will be set forth in part in the description
which
follows, and in part will be obvious from the description, or may be learned
by practice of
1
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
the aspects described below. The advantages described below will be realized
and attained
by means of the elements and combinations particularly pointed out in the
appended claims.
It is to be understood that both the foregoing general description and the
following detailed
description are exemplary and explanatory only and are not restrictive.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGs.1A-C are drawings of exemplary implant devices.
FIGs. 2A-D are drawings of exemplary implant devices comprising adjoined
polymer bodies.
FIG. 3 is a plot showing cumulative Goserelin released from formulations with
similar drug loadings, but different polymers.
FIG. 4 is a plot showing cumulative Goserelin released from formulations made
with
the same polymer, but different drug loadings.
FIG. 5 is a plot showing cumulative Goserelin released from formulations made
with
varying drug loadings and polymers.
FIG. 6 is a plot showing cumulative Goserelin released from formulations with
varying drug loadings and polymers
DETAILED DESCRIPTION
Before the present compounds, compositions, composites, articles, devices
and/or
methods are disclosed and described, it is to be understood that the aspects
described below
are not limited to specific compounds, compositions, composites, articles,
devices, methods,
or uses as such may, of course, vary. It is also to be understood that the
terminology used
herein is for the purpose of describing particular aspects only and is not
intended to be
limiting.
In this specification and in the claims that follow, reference will be made to
a
number of terms that shall be defined to have the following meanings:
Throughout this specification, unless the context requires otherwise, the word
"comprise," or variations such as "comprises" or "comprising," will be
understood to imply
the inclusion of a stated integer or step or group of integers or steps but
not the exclusion of
any other integer or step or group of integers or steps.
It must be noted that, as used in the specification and the appended claims,
the
singular forms "a," "an" and "the" include plural referents unless the context
clearly dictates
2
CA 02774495 2016-03-29
In some embodiments of the present invention, there can be provided the method
as described herein, wherein the disorder is a chronic disorder.
In some embodiments of the present invention, there is provided a method for
delivering a bioactive agent to a subject, comprising:
administering to the subject an implant device comprising:
a polymer body having at least two adjoined portions that each comprise a
bioactive agent therein and/or on a surface thereof, the bioactive agent being
releasable
from the at least two adjoined portions;
wherein a release profile characterizes the release of the bioactive agent
from
each of the portions; and
wherein at least two portions differ by release profile;
provided that the portions are not adjoined only in a core-sheath
configuration;
thereby delivering the bioactive agent to the subject.
In some embodiments of the present invention, there can be provided the method
as described herein, wherein the implant device is administered as an
injection.
In some embodiments of the present invention, there can be provided the method
as described herein, wherein the subject has a disorder and the administering
step
provides to the subject an amount of the bioactive agent effective to treat
the disorder.
In some embodiments of the present invention, there can be provided the method
as described herein, wherein the subject has a disorder; and prior to the
administering
step, a bioactive agent amount and release profile effective to treat the
disorder are
determined; and
the portions of the implant device are selected to provide the bioactive agent
amount and release profile effective to treat the disorder; thereby treating
the disorder.
In some embodiments of the present invention, there can be provided the method
as described herein, wherein the bioactive agent amount and release profile
are
determined through an evaluation of a dosage response that occurred when the
subject
was previously administered a dosage of the bioactive agent.
In some embodiments of the present invention, there can be provided the method
as described herein, wherein the disorder is a chronic disorder.
2a
CA 02774495 2016-03-29
In some embodiments of the present invention, there can be provided the method
as described herein, wherein the polymer body comprises at least two cross-
sectional
portions.
In some embodiments of the present invention, there can be provided the method
as described herein, wherein the polymer body comprises four cross-sectional
portions.
In some embodiments of the present invention, there can be provided the method
as described herein, wherein the polymer body comprises at least two segments.
In some embodiments of the present invention, there can be provided the method
as described herein, wherein at least one segment comprises two or more
portions.
In some embodiments of the present invention, there can be provided the method
as described herein, wherein at least one of the segments is configured in a
core-sheath
arrangement of two portions and at least one other segment is configured in a
non-core-
sheath arrangement of one or more portions.
In some embodiments of the present invention, there is provided a kit
comprising
a plurality of implant devices, wherein each implant device comprises:
a biodegradable polymer body having a bioactive agent therein and/or on a
surface thereof, the bioactive agent being releasable from the polymer body;
wherein a release profile characterizes the release of the bioactive agent
from the
polymer body; and
wherein at least two of the implants differ by release profile.
In some embodiments of the present invention, there can be provided the kit
described herein, wherein the plurality of implant devices are contained
within a
pharmaceutical carrier.
In some embodiments of the present invention, there can be provided the kit
described herein, further comprising an injection device for injecting the
plurality of
implant devices into a subject.
In some embodiments of the present invention, there can be provided the kit
described herein, wherein the plurality of implant devices are loaded into the
injection
device.
In some embodiments of the present invention, there can be provided the kit
described herein, wherein the at least two of the implants that differ by
release profile
2b
CA 02774495 2016-03-29
comprise different biodegradable polymers, different amounts of bioactive
agent,
different bioactive agents, different sizes, different surface
characteristics, or a
combination thereof.
In some embodiments of the present invention, there is provided an implant
device comprising:
a polymer body having at least two portions that each comprise a bioactive
agent
therein and/or on a surface thereof, the bioactive agent being releasable from
the at least
two adjoined portions;
wherein a release profile characterizes the release of the bioactive agent
from
each of the portions; and
wherein at least two portions differ by release profile;
provided that the portions are not adjoined only in a core-sheath
configuration.
In some embodiments of the present invention, there can be provided the
implant
device described herein, wherein the polymer body comprises at least two cross-
sectional
portions.
In some embodiments of the present invention, there can be provided the
implant
device described herein, wherein the polymer body comprises four cross-
sectional
portions.
In some embodiments of the present invention, there can be provided the
implant
device described herein, wherein the polymer body comprises at least two
segments.
In some embodiments of the present invention, there can be provided the
implant
device described herein, wherein at least one segment comprises two or more
portions.
In some embodiments of the present invention, there can be provided the
implant
device described herein, wherein at least one of the segments is configured in
a core-
sheath arrangement and at least one other segment is configured in a non-core-
sheath
arrangement.
In some embodiments of the present invention, there is provided a method for
delivering a bioactive agent to a subject, comprising:
administering to the subject a plurality of implant devices, wherein each
implant
device comprises:
2c
CA 02774495 2016-03-29
a biodegradable polymer body having a bioactive agent therein and/or on a
surface thereof, the bioactive agent being releasable from the polymer body;
wherein a release profile characterizes the release of the bioactive agent
from the
polymer body; and
wherein at least two of the implant devices differ by release profile;
thereby delivering the bioactive agent to the subject.
In some embodiments of the present invention, there is provided a kit
comprising
a plurality of implant devices, wherein each implant device comprises:
a biodegradable polymer body having a bioactive agent therein and/or on a
surface thereof, the bioactive agent being releasable from the polymer body;
wherein a release profile characterizes the release of the bioactive agent
from the
polymer body; and
wherein at least two of the implants differ by release profile.
In some embodiments of the present invention, there is provided an implant
device comprising a polymer body having at least two portions that each
comprise a
bioactive agent therein and/or on a surface thereof, the bioactive agent being
releasable
from the at least two adjoined portions, wherein a release profile
characterizes the release
of the bioactive agent from each of the portions and wherein at least two
portions differ
by release profile by releasing a different amount of the bioactive agent over
time,
provided that the portions are not adjoined only in a core-sheath
configuration, and
wherein the polymer body comprises at least two cross-sectional portions;
wherein said
implant device is in the form of a rod, where at least two cross-sectional
portions having
different release profiles are formed on one end of the rod; wherein the
implant device
has a cumulative release profile of the at least two portions and the at least
two cross-
sectional portions.
In some embodiments of the present invention, there is provided a kit
comprising
a plurality of implant devices, each implant device as described herein,
wherein at least
two of the implant devices in the kit exhibit a different release profile.
It is to be understood that both the foregoing general description and the
following detailed description are exemplary and explanatory only and are not
restrictive.
2d
CA 02774495 2016-03-29
BRIEF DESCRIPTION OF THE DRAWINGS
FIGs.1A-C are drawings of exemplary implant devices.
FIGs. 2A-D are drawings of exemplary implant devices comprising adjoined
polymer bodies.
FIG. 3 is a plot showing cumulative Goserelin released from formulations with
similar drug loadings, but different polymers.
FIG. 4 is a plot showing cumulative Goserelin released from formulations made
with the same polymer, but different drug loadings.
FIG. 5 is a plot showing cumulative Goserelin released from formulations made
with varying drug loadings and polymers.
FIG. 6 is a plot showing cumulative Goserelin released from formulations with
varying drug loadings and polymers
DETAILED DESCRIPTION
Before the present compounds, compositions, composites, articles, devices
and/or
methods are disclosed and described, it is to be understood that the aspects
described
below are not limited to specific compounds, compositions, composites,
articles, devices,
methods, or uses as such may, of course, vary. It is also to be understood
that the
terminology used herein is for the purpose of describing particular aspects
only and is not
intended to be limiting.
In this specification and in the claims that follow, reference will be made to
a
number of terms that shall be defined to have the following meanings:
Throughout this specification, unless the context requires otherwise, the word
"comprise," or variations such as "comprises" or "comprising," will be
understood to
imply the inclusion of a stated integer or step or group of integers or steps
but not the
exclusion of any other integer or step or group of integers or steps.
It must be noted that, as used in the specification and the appended claims,
the
singular forms "a," "an" and "the" include plural referents unless the context
clearly dictates
2e
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
otherwise. Thus, for example, reference to "a bioactive agent" includes
mixtures of two or
more such agents, and the like.
"Optional" or "optionally" means that the subsequently described event or
circumstance can or cannot occur, and that the description includes instances
where the
event or circumstance occurs and instances where it does not.
Ranges may be expressed herein as from "about" one particular value, and/or to
"about" another particular value. When such a range is expressed, another
aspect includes
from the one particular value and/or to the other particular value. Similarly,
when values
are expressed as approximations, by use of the antecedent "about," it will be
understood that
the particular value forms another aspect. It will be further understood that
the endpoints of
each of the ranges are significant both in relation to the other endpoint, and
independently
of the other endpoint.
A weight percent of a component, unless specifically stated to the contrary,
is based
on the total weight of the formulation or composition in which the component
is included.
An "implant device," as used herein, refers to a substantially solid device
comprised
of a polymer having a bioactive agent in and/or on a surface of the polymer.
The implant
devices can be any size. In some examples, the implant devices can be so sized
as to fit
within an injection device, such as a trochar. The implant devices can also
comprise other
additives, surface treatments, coatings, and the like. The implant devices can
be
administered to a subject through any appropriate route, including through
injection, oral
administration, and the like.
The term "biocompatible" refers a substance that is substantially non-toxic to
a
subject.
"Biodegradable" is generally referred to herein as a material that will erode
to
soluble species or that will degrade under physiologic conditions to smaller
units or
chemical species that are, themselves, non-toxic (biocompatible) to the
subject and capable
of being metabolized, eliminated, or excreted by the subject.
A "bioactive agent" refers to an agent that has biological activity. The
biological
agent can be used to treat, diagnose, cure, mitigate, prevent (L e.,
prophylactically),
ameliorate, modulate, or have an otherwise favorable effect on a disease,
disorder, infection,
and the like. A "releasable bioactive agent" is one that can be released from
a disclosed
polymer. Bioactive agents also include those substances which affect the
structure or
function of a subject, or a pro-drug, which becomes bioactive or more
bioactive after it has
been placed in a predetermined physiological environment.
3
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
A "release profile," as used herein, refers to the amount of bioactive agent
that is
released from the implant device over time. Thus, two or more implant devices
or polymer
bodies that differ by release profile will release a different amount of the
same bioactive
agent over time. Release profiles can be determined by measuring the amount of
bioactive
agent released over time using methods known in the art. When comparing the
release
profile of two different implant devices or polymer bodies, it can be useful
to plot the
amount of bioactive agent released from each device or body and compare each
plot to
determine if the two different implant devices or polymer bodies exhibit the
same or
different release profiles. Two or more devices or bodies that exhibit
different release
profiles will exhibit measurably different release profiles. For example,
different release
profiles can be characterized by a different amount of released (or remaining)
bioactive
agent at any point during the release. When comparing two or more implant
devices or
polymers, the amount of bioactive agent released at any point in time during
the release can
differ by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, or greater, including
differences of 100% or more.
A "portion" of an implant device, as used herein, refers to a part of an
implant
device. When an implant device has "portions," at least two of the portions
differ by release
profile. In some examples, the "portion" refers to a cross-section of the
implant device, a
segment of the implant device, or a combination thereof. In a specific
example, the
"portion" refers to a cross-section of an implant device that comprises at
least one other
cross-sectional portion (e.g., two or four cross-sectional portions). In
another specific
example, the "portion" refers to a segment of an implant device that is
defined by one or
more ends, wherein at least one of the ends adjoins, i.e., is physically
connected to, an end
of another portion. Each segment can itself comprise one or more portions,
such as cross-
sections.
A "kit," as used herein, refers to a package containing one or more disclosed
implant
devices. The implant devices of the kit can optionally be present in a
suitable
pharmaceutical carrier. The packaging of the kit can be any suitable packaging
material,
such as a sterile package, a syringe, or a trochar, among others.
Disclosed are compounds, compositions, and components that can be used for,
can
be used in conjunction with, can be used in preparation for, or are products
of the disclosed
methods and compositions. These and other materials are disclosed herein, and
it is
understood that when combinations, subsets, interactions, groups, etc. of
these materials are
disclosed that while specific reference of each various individual and
collective
4
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
combinations and permutation of these compounds may not be explicitly
disclosed, each is
specifically contemplated and described herein. For example, if a number of
different
polymers and agents are disclosed and discussed, each and every combination
and
permutation of the polymer and agent are specifically contemplated unless
specifically
indicated to the contrary. Thus, if a class of molecules A, B, and C are
disclosed as well as
a class of molecules D, E, and F and an example of a combination molecule, A-D
is
disclosed, then even if each is not individually recited, each is individually
and collectively
contemplated. Thus, in this example, each of the combinations A-E, A-F, B-D, B-
E, B-F,
C-D, C-E, and C-F are specifically contemplated and should be considered
disclosed from
disclosure of A, B, and C; D, E, and F; and the example combination A-D.
Likewise, any
subset or combination of these is also specifically contemplated and
disclosed. Thus, for
example, the sub-group of A-E, B-F, and C-E are specifically contemplated and
should be
considered disclosed from disclosure of A, B, and C; D, E, and F; and the
example
combination A-D. This concept applies to all aspects of this disclosure
including, but not
limited to, steps in methods of making and using the disclosed compositions.
Thus, if there
are a variety of additional steps that can be performed it is understood that
each of these
additional steps can be performed with any specific embodiment or combination
of
embodiments of the disclosed methods, and that each such combination is
specifically
contemplated and should be considered disclosed.
The present invention relates to implant devices for achieving a desired
release
profile of a bioactive agent. In one aspect, a plurality of implant devices
can be
administered to a subject, wherein at least two of the implant devices provide
a different
release profile for a given bioactive agent. By using at least two implant
devices that
provide a different release profile than the other(s), the release profile of
the plurality of
implant devices will be different relative to a plurality of implant devices
that all
individually exhibit the same release profile, or relative to an individual
implant device
capable of exhibiting only a single release profile. When a plurality of
implant devices are
used in combination or are present together in a kit, the implant devices can
have the same
size and/or shape, or have a different size and/or shape.
In a further aspect, a plurality of modular polymer portions can be adjoined
into a
single implant device, wherein at least two of the polymer portions exhibit a
different
release profile. According to this aspect, formed polymer portions can be
connected to each
other to provide a single unit. In a similar aspect, an implant device can be
prepared by co-
manufacturing two or more polymers together into a single unit, wherein at
least two of the
5
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
polymers exhibit a different release profile. Such modular or co-manufactured
single unit
implant devices can in turn be used individually or in combination with other
implant
devices, depending on the desired release profile.
As will be appreciated, a large number of release profiles can be achieved
through
the present invention. Generally, the implant devices described herein allow
for a variety of
controlled-release, extended-release, modified-release, sustained-release,
pulsatile-release,
delayed-release, or programmed-release profiles that can be provided through
the use of
multiple implant devices, multiple polymer bodies that can be adjoined, or a
combination
thereof.
The implant device generally comprises one or more biodegradable polymer
bodies
having a releasable bioactive agent in or on a surface of the polymer body.
Upon
implanting the implant device into a subject, the bioactive agent is released
from the
polymer body, which then provides for a desired therapeutic result.
The polymer body of the implant device can comprise any suitable biocompatible
-- and biodegradable or non-biodegradable polymer. The polymers can be
homopolymers or
copolymers, including block or blocky co- or ter- polymers, random co- or ter-
polymers,
star polymers, or dendrimers. Any desired molecular weight polymer can be
used,
depending on the desired properties of the polymer body. In certain aspects,
if a high
strength polymer body is desired, then high molecular weight polymers can be
used, for
-- example, to meet strength requirements. In other aspects, low or medium
molecular weight
polymers can be used when, for example, when resorption time of the polymer,
rather than
material strength is desired.
The molecular weight of a polymer can be important given that molecular weight
influences the biodegradation rate of a biodegradable polymer. For a
diffusional
-- mechanism of bioactive agent release, the polymer should remain intact
until all of the drug
is released from the polymer and then degrade. The drug can also be released
from the
polymer as the polymer bioerodes. By an appropriate selection of polymeric
materials, a
polymer formulation can be made such that the resulting polymer exhibits both
diffusional
release and biodegradation release properties. Molecular weights can be
measured by
-- methods known in the art, including gel permeation chromatography,
viscosity, light-
scattering, among other methods.
The polymer of the polymer body can be formulated so as to degrade within a
desired time interval, once present in a subject, or a biological medium. In
some aspects,
the time interval can be from about less than one day to about 1 month. Longer
time
6
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
intervals can extend to 6 months, including for example, polymers that degrade
from about
.0rJ. to about 6 months, or from about 1 to about 6 months. In other aspects,
the polymer can
degrade in longer time intervals, up to 2 years or longer, including, for
example, from about
to about 2 years, or from about 1 month to about 2 years.
The desired bioactive agent release mechanism can influence the selection of
the
polymer and/or the selection of each implant device or portion thereof, as
discussed above.
A biocompatible polymer, for example, can be selected so as to release or
allow the release
of a bioactive agent therefrom at a desired lapsed time after the implant
device has been
implanted in a subject. For example, the polymer can be selected to release or
allow the
release of the bioactive agent prior to the bioactive agent beginning to
diminish its activity,
as the bioactive agent begins to diminish in activity, when the bioactive
agent is partially
diminished in activity, for example at least 25%, at least 50% or at least 75%
diminished,
when the bioactive agent is substantially diminished in activity, or when the
bioactive agent
is completely gone or no longer has activity.
Examples of suitable polymers include without limitation polyesters,
polyhydroxyalkanoates, polyhydroxybutyrates, polydioxanones,
polyhydroxyvalerates,
polyanhydrides, polyorthoesters, polyphosphazenes, polyphosphates,
polyphosphoesters,
polydioxanones, polyphosphoesters, polyphosphates, polyphosphonates,
polyphosphates,
polyhydroxyalkanoates, polycarbonates, polyalkylcarbonates,
polyorthocarbonates,
polyesteramides, polyamides, polyamines, polypeptides, polyurethanes,
polyalkylene
alkylates, polyalkylene oxalates, polyalkylene succinates, polyhydroxy fatty
acids,
polyacetals, polycyanoacrylates, polyketals, polyetheresters, polyethers,
polyalkylene
glycols, polyalkylene oxides, polyethylene glycols, polyethylene oxides,
polypeptides,
polysaccharides, or polyvinyl pyrrolidones. Other non-biodegradable but
durable polymers
include without limitation ethylene-vinyl acetate co-polymer,
polytetrafluoroethylene,
polypropylene, polyethylene, and the like. Likewise, other suitable non-
biodegradable
polymers include without limitation silicones and polyurethanes.
The implant device can comprise a variety of polysaccharides such as
cellulose,
modified cellulose including ethyl cellulose, hydroxyethyl cellulose,
hydroxypropyl
cellulose, methylcellulose, or hydroxypropylmethyl cellulose. The implant
device can also
comprise amylase, starch, maltodextrin, glycogen, chitin, or modified
polysaccharides such
as hydrophobically-modified polysaccharides. Examples of hydrophobically-
modified
polysaccharides include maltodextrins that have been hydrophobically-modified
with C1-
Cio alkyl sidechains, saturated sidechains, unsaturated sidechains, fatty acid
side chains, or
7
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
the like.
Other specific examples of suitable polymers include CAMEO polymers (ester-
amide polymers), POLYACTIVE polymers, and SYNBIOSYS polymers (ester-urethane
polymers. Further examples include polyesters with or without side-chains
including
poly(glycolide), poly(lactide), which has a pendent methyl group, and
glycolides having C2-
C12 side chains, such as hexyl-modified glycolide.
Further specific examples of suitable polymers include one or more of a
poly(lactide), a poly(glycolide), a poly(lactide-co-glycolide), a
poly(caprolactone), a
poly(orthoester), a poly(phosphazene), a poly(hydroxybutyrate) or a copolymer
containing a
poly(hydroxybutarate), a poly(lactide-co-caprolactone), a polycarbonate, a
polyesteramide,
a polyanhydride, a poly(dioxanone), a poly(alkylene alkylate), a copolymer of
polyethylene
glycol and a polyorthoester, a biodegradable polyurethane, a poly(amino acid),
a
polyamide, a polyesteramide, a polyetherester, a polyacetal, a
polycyanoacrylate, a
poly(oxyethylene)/poly(oxypropylene) copolymer, polyacetals, polyketals,
polyphosphoesters, polyhydroxyvalerates or a copolymer containing a
polyhydroxyvalerate,
polyalkylene oxalates, polyalkylene succinates, poly(maleic acid), and
copolymers,
terpolymers, combinations, or blends thereof.
When a block copolymer is desired, examples of useful biodegradable polymers
are
those that comprise one or more blocks of hydrophilic or water soluble
polymers, including,
but not limited to, polyethylene glycol, (PEG), or polyvinyl pyrrolidone
(P'VP), in
combination with one or more blocks another biocompabible or biodegradable
polymer that
comprises lactide, glycolide, caprolactone, or a combination thereof.
In a preferred aspect, useful biocompatible polymers are those that comprise
one or
more residues of lactic acid, glycolic acid, lactide, glycolide, caprolactone,
hydroxybutyrate,
hydroxyvalerates, dioxanones, polyethylene glycol (PEG), polyethylene oxide,
or a
combination thereof. In a still further aspect, useful biocompatible polymers
are those that
comprise one or more residues of lactide, glycolide, caprolactone, or a
combination thereof.
Lactide-based polymers can comprise any lactide residue, including all racemic
and
stereospecific forms of lactide, including, but not limited to, L-lactide, D-
lactide, and D,L-
lactide, or a mixture thereof. Useful polymers comprising lactide include, but
are not
limited to poly(L-lactide), poly(D-lactide), and poly(DL-lactide); and
poly(lactide-co-
glycolide), including poly(L-lactide-co-glycolide), poly(D-lactide-co-
glycolide), and
poly(DL-lactide-co-glycolide); or copolymers, terpolymers, combinations, or
blends
thereof. Lactide/glycolide polymers can be conveniently made by melt
polymerization
8
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
through ring opening of lactide and glycolide monomers. Additionally, racemic
DL-lactide,
L-lactide, and D-lactide polymers are commercially available. The L-polymers
are more
crystalline and resorb slower than DL- polymers. In addition to copolymers
comprising
glycolide and DL-lactide or L-lactide, copolymers of L-lactide and DL-lactide
are
commercially available. Homopolymers of lactide or glycolide are also
commercially
available.
In a particular aspect, when the biodegradable polymer is poly(lactide-co-
glycolide),
or a mixture of poly(lactide) and poly(glycolide), the amount of lactide and
glycolide in the
polymer can vary. In a further aspect, the biodegradable polymer contains 0 to
100 mole %,
40 to 100 mole %, 50 to 100 mole %, 60 to 100 mole %, 70 to 100 mole %, or 80
to 100
mole % lactide and from 0 to 100 mole %, 0 to 60 mole %, 10 to 40 mole %, 20
to 40 mole
%, or 30 to 40 mole % glycolide, wherein the amount of lactide and glycolide
is 100 mole
%. In a further aspect, the biodegradable polymer can be poly(lactide), 95:5
poly(lactide-
co-glycolide) 85:15 poly(lactide-co-glycolide), 75:25 poly(lactide-co-
glycolide), 65:35
poly(lactide-co-glycolide), or 50:50 poly(lactide-co-glycolide), where the
ratios are mole
ratios.
In another aspect, the polymer can be a poly(caprolactone) or a poly(lactide-
co-
caprolactone). In one aspect, the polymer can be a poly(lactide-caprolactone),
which, in
various aspects, can be 95:5 poly(lactide-co-caprolactone), 85:15 poly(lactide-
co-
caprolactone), 75:25 poly(lactide-co- caprolactone), 65:35 poly(lactide-co-
caprolactone),
or 50:50 poly(lactide-co- caprolactone), where the ratios are mole ratios.
The bioactive agent used with the implant device is not critical, and a large
variety
of bioactive agents can be used. Typically, the bioactive agent is one that
can be released
from the implant device or portion thereof, usually as the device degrades or
bioerodes, but
can also release through a simple diffusion mechanism, or other mechanism. In
one aspect,
the processing of the polymer and bioactive agent can be performed under
conditions such
that the agent is intimately mixed or dispersed throughout the polymer, e.g.,
homogenously
or substantially homogenously. Alternatively, the processing of the polymer
and bioactive
agent can be performed under conditions such that the agent is localized on or
in only a
portion or portions of the polymer body or implant device. Thus, the polymer
can include
areas that are rich in bioactive agent, and areas that are not as rich. The
implant device can
comprise a large number of bioactive agents either singly or in combination.
Various forms of the bioactive agent can be used, which are capable of being
released from polymer into adjacent tissues or fluids. To that end, a liquid
or solid bioactive
9
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
agent can be incorporated into the implants described herein. The bioactive
agents are at
least very slightly water soluble, and preferably moderately water soluble.
The bioactive
agents can include salts of the active ingredient. As such, the bioactive
agents can be acidic,
basic, or amphoteric salts. They can be nonionic molecules, polar molecules,
or molecular
complexes capable of hydrogen bonding. The bioactive agent can be included in
the
compositions in the form of, for example, an uncharged molecule, a molecular
complex, a
salt, an ether, an ester, an amide, polymer drug conjugate, or other form to
provide the
effective biological or physiological activity.
Examples of bioactive agents that incorporated into systems herein include,
but are
not limited to, peptides, proteins such as hormones, enzymes, antibodies,
antibody
fragments, antibody conjugates, nucleic acids such as aptamers, iRNA, siRNA,
DNA,
RNA, antisense nucleic acid or the like, antisense nucleic acid analogs or the
like, VEGF
inhibitors, macrocyclic lactones,dopamine agonists, dopamine antagonists, low-
molecular
weight compounds, or high-molecular-weight compounds. Bioactive agents
contemplated
for use in the disclosed implants include anabolic agents, antacids, anti-
asthmatic agents,
anti-cholesterolemic and anti-lipid agents, anti-coagulants, anti-convulsants,
anti-diarrheals,
anti-emetics, anti-infective agents including antibacterial and antimicrobial
agents, anti-
inflammatory agents, anti-manic agents, antimetabolite agents, anti-nauseants,
anti-
neoplastic agents, anti-obesity agents, anti-pyretic and analgesic agents,
anti-spasmodic
agents, anti-thrombotic agents, anti-tussive agents, anti-uricemic agents,
anti-anginal agents,
antihistamines, appetite suppressants, biologicals, cerebral dilators,
coronary dilators,
bronchiodilators, cytotoxic agents, decongestants, diuretics, diagnostic
agents,
erythropoietic agents, expectorants, gastrointestinal sedatives, hyperglycemic
agents,
hypnotics, hypoglycemic agents, immunomodulating agents, ion exchange resins,
laxatives,
mineral supplements, mucolytic agents, neuromuscular drugs, peripheral
vasodilators,
psychotropics, sedatives, stimulants, thyroid and anti-thyroid agents, tissue
growth agents,
uterine relaxants, vitamins, or antigenic materials.
Other bioactive agents include androgen inhibitors, polysaccharides, growth
factors,
hormones, anti-angiogenesis factors, dextromethorphan, dextromethorphan
hydrobromide,
noscapine, carbetapentane citrate, chlophedianol hydrochloride,
chlorpheniramine maleate,
phenindamine tartrate, pyrilamine maleate, doxylamine succinate,
phenyltoloxamine citrate,
phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudo
ephedrine
hydrochloride, ephedrine, codeine phosphate, codeine sulfate morphine, mineral
supplements, cholestryramine, N-acetylprocainamide, acetaminophen, aspirin,
ibuprofen,
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
phenyl propanolamine hydrochloride, caffeine, guaifenesin, aluminum hydroxide,
magnesium hydroxide, peptides, polypeptides, proteins, amino acids, hormones,
interferons,
cytokines, and vaccines.
Representative drugs that can be used as bioactive agents in the implants
include,
but are not limited to, peptide drugs, protein drugs, desensitizing materials,
antigens, anti-
infective agents such as antibiotics, antimicrobial agents, antiviral,
antibacterial,
antiparasitic, antifungal substances and combination thereof, antiallergenics,
androgenic
steroids, decongestants, hypnotics, steroidal anti-inflammatory agents, anti-
cholinergics,
sympathomimetics, sedatives, miotics, psychic energizers, tranquilizers,
vaccines,
estrogens, progestational agents, humoral agents, prostaglandins, analgesics,
antispasmodics, antimalarials, antihistamines, cardioactive agents,
nonsteroidal anti-
inflammatory agents, antiparkinsonian agents, antihypertensive agents,13-
adrenergic
blocking agents, nutritional agents, and the benzophenanthridine alkaloids.
The agent can
further be a substance capable of acting as a stimulant, sedative, hypnotic,
analgesic,
anticonvulsant, and the like.
Other bioactive agents include but are not limited to analgesics such as
acetaminophen, acetylsalicylic acid, and the like; anesthetics such as
lidocaine, xylocaine,
and the like; anorexics such as dexadrine, phendimetrazine tartrate, and the
like;
antiarthritics such as methylprednisolone, ibuprofen, and the like;
antiasthmatics such as
terbutaline sulfate, theophylline, ephedrine, and the like; antibiotics such
as sulfisoxazole,
penicillin G, ampicillin, cephalosporins, amikacin, gentamicin, tetracyclines,
chloramphenicol, erythromycin, clindamycin, isoniazid, rifampin, and the like;
antifungals
such as amphotericin B, nystatin, ketoconazole, and the like; antivirals such
as acyclovir,
amantadine, and the like; anticancer agents such as cyclophosphamide,
methotrexate,
etretinate, and the like; anticoagulants such as heparin, warfarin, and the
like;
anticonvulsants such as phenytoin sodium, diazepam, and the like;
antidepressants such as
isocarboxazid, amoxapine, and the like;antihistamines such as diphenhydramine
HC1,
chlorpheniramine maleate, and the like; hormones such as insulin, progestins,
estrogens,
corticoids, glucocorticoids, androgens, and the like; tranquilizers such as
thorazine,
diazepam, chlorpromazine HC1, reserpine, chlordiazepoxide HC1, and the like;
antispasmodics such as belladonna alkaloids, dicyclomine hydrochloride, and
the like;
vitamins and minerals such as essential amino acids, calcium, iron, potassium,
zinc, vitamin
B12, and the like; cardiovascular agents such as prazosin HC1, nitroglycerin,
propranolol
HC1, hydralazine HC1, pancrelipase, succinic acid dehydrogenase, and the like;
peptides and
11
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
proteins such as LHRH, somatostatin, calcitonin, growth hormone, glucagon-like
peptides,
growth releasing factor, angiotensin, FSH, EGF, bone morphogenic protein
(BMP),
erythopoeitin (EPO), interferon, interleukin, collagen, fibrinogen, insulin,
Factor VIII,
Factor IX, Enbrel , Rituxan , Herceptin , alpha-glucosidase, Cerazyme/Ceredose
,
vasopressin, ACTH, human serum albumin, gamma globulin, structural proteins,
blood
product proteins, complex proteins, enzymes, antibodies, monoclonal
antibodies, and the
like; prostaglandins; nucleic acids; carbohydrates; fats; narcotics such as
morphine, codeine,
and the like, psychotherapeutics; anti-malarials, L-dopa, diuretics such as
furosemide,
spironolactone, and the like; antiulcer drugs such as rantidine HC1,
cimetidine HC1, and the
like.
The bioactive agent can also be an inununomodulator, including, for example,
cytokines, interleukins, interferon, colony stimulating factor, tumor necrosis
factor, and the
like; allergens such as cat dander, birch pollen, house dust mite, grass
pollen, and the like;
antigens of bacterial organisms such as Streptococcus pneumoniae, Haemophilus
influenzae, Staphylococcus aureus, Streptococcus pyrogenes, Corynebacterium
diphteriae,
Listeria monocytogenes, Bacillus anthracis, Clostridium tetani, Clostridium
botulinum,
Clostridium perfringens. Neisseria meningitides, Neisseria gonorrhoeae,
Streptococcus
mutans. Pseudomonas aeruginosa, Salmonella typhi, Haemophilus parainfluenzae,
Bordetella pertussis, Francisella tularensis, Yersinia pestis, Vibrio
cholerae, Legionella
pneumophila, Mycobacterium tuberculosis, Mycobacterium leprae, Treponema
pallidum,
Leptspirosis interrogans, Borrelia burgddorferi, Campylobacter jejuni, and the
like;
antigens of such viruses as smallpox, influenza A and B, respiratory synctial,
parainfluenza,
measles, HW, SARS, varicella-zoster, herpes simplex 1 and 2, cytomeglavirus,
Epstein-
Barr, rotavirus, rhinovirus, adenovirus, papillomavirus, poliovirus, mumps,
rabies, rubella,
coxsackieviruses, equine encephalitis, Japanese encephalitis, yellow fever,
Rift Valley
fever, lymphocytic choriomeningitis, hepatitis B, and the like; antigens of
such fungal,
protozoan, and parasitic organisms such as Cryptococcuc neoformans,
Histoplasma
capsulatum, Candida albicans, Candida tropicalis, Nocardia asteroids,
Rickettsia ricketsii,
Rickettsia typhi, Mycoplasma pneumoniae, Chlamyda psittaci, Chlamydia
trachomatis,
Plasmodium fakiparum, Trypanasoma brucei, Entamoeba histolytica, Toxoplasma
gondii,
Trichomonas vaginalis, Schistosoma mansoni, and the like. These antigens may
be in the
form of whole killed organisms, peptides, proteins, glycoproteins,
carbohydrates, or
combinations thereof.
In a further specific aspect, the bioactive agent comprises an antibiotic. The
12
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
antibiotic can be, for example, one or more of Amikacin, Gentamicin,
Kanamycin,
Neomycin, Netilmicin, Streptomycin, Tobramycin, Paromomycin, Ansamycins,
Geldanamycin, Herbimycin, Carbacephem, Loracarbef, Carbapenems, Ertapenem,
Doripenem, Imipenem/Cilastatin, Meropenem, Cephalosporins (First generation),
Cefadroxil, Cefazolin, Cefalotin or Cefalothin, Cefalexin, Cephalosporins
(Second
generation), Cefaclor, Cefamandole, Cefoxitin, Cefprozil, Ceffiroxime,
Cephalosporins
(Third generation), Cefixime, Cefdinir, Cefditoren, Cefoperazone, Cefotaxime,
Cefpodoxime, Ceftazidime, Ceftibuten, Ceftizoxime, Ceftriaxone, Cephalosporins
(Fourth
generation), Cefepime, Cephalosporins (Fifth generation), Ceftobiprole,
Glycopeptides,
Teicoplanin, Vancomycin, Macrolides, Azithromycin, Clarithromycin,
Dirithromycin,
Erythromycin, Roxithromycin, Troleandomycin, Telithromycin, Spectinomycin,
Monobactams, Aztreonam, Penicillins, Amoxicillin, Ampicillin, Azlocillin,
Carbenicillin,
Cloxacillin, Dicloxacillin, Flucloxacillin, Mezlocillin, Meticillin,
Nafcillin, Oxacillin,
Penicillin, Piperacillin, Ticarcillin, Polypeptides, Bacitracin, Colistin,
Polymyxin B,
Quinolones, Ciprofloxacin, Enoxacin, Gatifloxacin, Levofloxacin, Lomefloxacin,
Moxifloxacin, Norfloxacin, Ofloxacin, Trovafloxacin, Sulfonamides, Mafenide,
Prontosil
(archaic), Sulfacetamide, Sulfamethizole, Sulfanilimide (archaic),
Sulfasalazine,
Sulfisoxazole, Trimethoprim, Trimethoprim-Sulfamethoxazole (Co-trimoxazole)
(TMP-
SMX), Tetracyclines, including Demeclocycline, Doxycycline, Minocycline,
Oxytetracycline, Tetracycline, and others; Arsphenamine, Chloramphenicol,
Clindamycin,
Lincomycin, Ethambutol, Fosfomycin, Fusidic acid, Furazolidone, Isoniazid,
Linezolid,
Metronidazole, Mupirocin, Nitrofurantoin, Platensimycin, Pyrazinamide,
Quinupristin/Dalfopristin, Rifampicin (Rifampin in U.S.), Tinidazole,
Ropinerole,
Ivermectin, Moxidectin, Afamelanotide, Cilengitide, or a combination thereof.
In one
aspect, the bioactive agent can be a combination of Rifampicin (Rifampin in
U.S.) and
Minocycline.
The amount of drug incorporated into the implant device varies depending upon
a
particular drug, the desired therapeutic affect and the desired time span.
Since a variety of
devices in a variety of sizes and shapes are intended to provide dosage
regimens for therapy
for a variety purposes, there is no critical upper limit in the amount of drug
incorporated
into the device. The lower limit too will depend upon the activity of the drug
and the time
span of its release from the device. Those skilled in the pharmaceutical arts
will know how
to determine toxic levels of a given drug as well as the minimum effective
dose.
It is contemplated that other components such as, for example, excipients,
13
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
pharmaceutically carriers or adjuvants, microparticles, and the like, can be
combined with
the polymer and/or the bioactive agent. Thus, in certain aspects, the
bioactive agent can be
present as a component in a pharmaceutical composition. Pharmaceutical
compositions can
be conveniently prepared in a desired dosage form, including, for example, a
unit dosage
form or controlled release dosage form, and prepared by any of the methods
well known in
the art of pharmacy. In general, pharmaceutical compositions are prepared by
uniformly
and intimately bringing the bioactive agent into association with a liquid
carrier or a finely
divided solid carrier, or both. The pharmaceutical carrier employed can be,
for example, a
solid, liquid, or gas. Examples of solid carriers include lactose, terra alba,
sucrose, talc,
gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples
of liquid
carriers are sugar syrup, peanut oil, olive oil, and water. Examples of
gaseous carriers
include carbon dioxide and nitrogen. Other pharmaceutically acceptable
carriers or
components that can be mixed with the bioactive agent can include, for
example, a fatty
acid, a sugar, a salt, a water-soluble polymer such as polyethylene glycol, a
protein,
polysacharride, or carboxmethyl cellulose, a surfactant, a plasticizer, a high-
or low-
molecular-weight porosigen such as polymer or a salt or sugar, or a
hydrophobic low-
molecular-weight compound such as cholesterol or a wax.
The polymer and bioactive agent can be co-processed by a variety of
techniques,
such as, for example, melt extruding, injection molding, compression molding,
or roller
compacting the admixture into a desired shape or structure, as will be
discussed below. In
certain aspects, the polymer and bioactive agent are combined or admixed to
form a blend
or admixture. Admixing methods can be performed using techniques known in the
art. For
example, the polymer and bioactive agent can be dry blended (i.e., mixing of
particulates of
the polymer and the agent) using, for example, a Patterson-Kelley V-blender,
or granulated
prior to processing.
To prepare the implant device from the polymer, a variety of methods can be
used.
In a preferred aspect, the implants are prepared by extrusion methods, for
example through
heat extrusion or solvent extrusion. The bioactive agent and polymer can first
be blended,
for example using a Turbula Shaker Mixer Type T2 F (available from a number of
commercial sources, including Artisan Scientific Corporation 301 E. Mercury
Drive
Champaign, IL 61822). The blend can be dried, formed into a film, or formed
into another
appropriate solid and subsequently extruded. The bioactive agent and the
polymer can also
be added separately to the extruder and subsequently combined and blended
during the
extrusion process.
14
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
The blend can be extruded using a suitable plastometer, for example, a Tinius
Olsen
Model UE-4-78 melt plastometer (available from Tinius Olsen Corporation, 1065
Easton
Road, PO Box 1009, Horsham, PA 19044-8009). Other suitable extruders use in
the
pharmaceutical arts can also be used. Examples include single-screw extruders,
such as a
RANDCASTLE extruder (Cedar Grove, New Jersey, U.S.A.), twin-screw extruders,
or even
combinations of two or more extruders. The implant device can be prepared
using a single
pass through an extruder, or extrusion can be performed multiple times to
further blend
and/or process the bioactive agent and the polymer mixture. Additionally,
molding
techniques can also be used to prepare the implant devices, including for
example, injection
molding, compression molding, and the like.
The extruded formulation can also be prepared by the "drawing" technique,
wherein
the extruded article is pulled or "drawn" out at a rate that is slightly
faster than the actual
rate of extrusion. This drawing action can orient the polymer (and can
possibly induce
crystallization in certain polymers) which can affect release characteristics
of that
formulation.
After extrusion, the implant device can be further processed. In one aspect,
multiple
implant devices can be prepared from a single extruded article by cutting the
extruded
article into more than one segment. When the bioactive agent is homogenously
distributed
in the extruded article, the size of the segment of the extruded article will
determine the
amount of bioactive agent in that segment and will therefore affect the
release profile of the
segment. The surface area of the segment will also likewise affect the release
profile of the
bioactive agent.
In a further aspect, multiple implant devices can be prepared from a single
extruded
article by cutting the extruded article into a plurality of disconnected
segments and the
plurality of segments can then be administered to a subject. The release
profile of the
plurality of segments, in this aspect, can be affected by size, surface area,
and surface
treatment (if any), among other variables. For example, if a single extruded
article is cut
into a 1 cm, 2 cm, and 3 cm segments, the release profile exhibited by the cut
segments will
be different than a release profile exhibited by the single extruded article
(6 cm) and will
also likely be different than three 3 cm segments prepared from the same 6 cm
extruded
article. It will be apparent however, in other aspects, that the plurality of
implant devices
can comprise individual implant devices prepared from more than one extruded
article.
In one aspect, modular polymer body portions can be used, such that one or
more
portions can be adjoined together. In this aspect, multiple extruded implant
articles can be
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
connected. Preferably, the adjoined implant devices are not adjoined only
through a coaxial
configuration, wherein one portion forms a sheath around a core. However, the
core/sheath
arrangement can be used provided that at least one further arrangement is
present, for
example, if two implant device segments form a core/sheath having two ends and
one or
more additional implant devices are connected to at least one of the ends,
wherein at least
one of the additional implant devices is not formed in a core/sheath
arrangement. In a
further aspect, when the implant device is a rod having two ends, one or more
of the ends
can be connected to the end of another implant device. A variety of methods
for adjoining
individual implant devices can be used, for example, through the use of
biocompatible or
biodegradable adhesives, through melt processing, thermal annealing, solvent
annealing,
solution processing, among other methods.
In another similar aspect, the implant device can comprise different polymer
body
portions that have been co-manufacturing to form a single composite article. A
variety of
arrangements can be prepared according to this aspect, including for example a
polymer
body or portion thereof having more than one cross-section when viewed
perpendicular to
the elongated axis, and/or a core sheath or other suitable arrangement, as
will be discussed
below. Preferably, two or more polymer bodies are co-extruded together to form
a
composite implant device. As discussed above, at least two the polymer body
portions in
this aspect exhibit a different release profile.
Various extrusion methods can be used to prepare implant devices comprising co-
extruded polymer bodies. For an implant device having more than one cross-
sections when
viewed from an end of the implant device, wherein each section which comprises
a polymer
portion, can be formed by simultaneously delivering a portion of extrudate
from one
extruder and a portion of extrudate from another extruder and then joining the
two or more
portions near a die-head outlet. For an implant device having two or more
polymer body
portions adjoined at their ends (segments), two or more extruders can deliver
polymer from
a feed source to a die-head that can then produce a single-stranded article by
switching
between the feed sources of the two or more extruders. For a core/sheath
arrangement or
other similar arrangement, typical coaxial extrusion methods can be used,
wherein two or
more polymer body portions are extruded at the same time. According to this
arrangement,
a coaxial die-head can be used that forms the interior portion or core then
the die-head
passes extrudate from another extruder around the core thereby forming the
outer sheath.
The precise shape of the implant device will depend on a variety of factors
including
the desired therapeutic effect, the intended physiological environment for the
implant
16
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
device, the surgical procedure and convenience. According to various aspects,
however, the
implant device can be in the shape of a rod, a fiber, a cylinder, a bead, a
ribbon, a disc, a
wafer, a free-formed shaped solid, or a variety of other shaped solids. The
device can have
any regular or irregular shape and can have any cross section such as
circular, rectangular,
triangular, oval, bilobe, trilobe, cloverleaf, c-shaped, pie-slice, crescent-
moon, and the like.
In a specific aspect, the implant device is in the shape of a rod having an
elongated body
and two ends. With reference to FIG. 1, for example, a variety of rod-shaped
implant
devices 100 can be used. According to FIG. 1A, a substantially homogenous
implant device
100 comprising a single polymer body having one portion 110 can be used with
one or more
other implant devices that provide a different release profile. According to
FIG. 1B and
FIG. 1C, an implant device 100 comprising a polymer body 110 having two cross-
sectional
portions (112, 114), or four cross-sectional portions (116, 118, 120, 122) can
be used. Such
devices can be made according to the extrusion methods discussed above.
Preferably, when
an implant device comprises at least two cross-sectional portions, at least
one portion
exhibits a different release profile than another.
With reference to FIG. 2, an implant device 200 can comprise two or more
polymer
body portions that are adjoined. Such implant devices can be prepared by
either connecting
two or more modular portions, or by co-manufacturing, for example co-
extruding, two or
more portions together. With reference to FIG. 2A, for example, two rod-
segments of a
polymer body (205, 210) can be adjoined at their respective ends. With
reference to FIGs.
2B-2D, such an end-to-end arrangement can also be used in combination with
implant
device segments that are different cross-sectionally, for example a segment
having two or
more cross sections (FIG. 2B, 215, 220 and FIG. 2D, 222, 224, 226, 228) or a
portion
having a core 235 surrounded by a sheath 230, as shown in FIG. 2C. One or more
portions
or sections of the implant device, as discussed above, can exhibit a different
release profile
than another portion or section.
Generally, the size of the implant device will depend on its intended use, and
as such
will vary. For implant devices that will be used primarly for drug-delivery,
for example,
and will be administered through an injection device, the implant device will
be so-sized as
to fit within an injection device, such as a trochar (e.g., in the centimeter
range). The size of
each implant device in a plurality can affect the amount and therefore the
release profile of
the bioactive agent, as discussed above. Thus, the size of an implant device
can be selected
to provide a desired release profile. The precise shape of implant device for
the kit will
depend on a variety of factors including the desired therapeutic effect, the
intended
17
CA 02774495 2016-03-29
physiological environment for the implantable article, the surgical procedure
and
convenience.
The disclosed implant devices can be used in combination with virtually any
further
implant processing method. Thus, one or more surfaces of the implant device
can be coated
with a coating composition. The coating composition can further comprise other
ingredients, such as other bioactive agents, additives, and the like,
including for example,
salts, sugars, polysaccharides, water-soluble additives, non-water-soluble
additives, partially
water-soluble additives water-soluble polymers, non-water soluble polymers,
and partially
water-soluble polymers, among others.
The implant devices can also be solvent-treated on at least a portion, or all,
of the implant
device surface. Solvent-treatment methods for implant devices are described in
Tice et al. "Methods
for manufacturing delivery devices and devices thereof' U.S. Patent
Application Publication No.
20060029637, for its teachings of solvent-treatment methods. In various
aspects, the implant device
can be treated on only a portion of the device surface, such as the end or the
longitudinal side of the
implant device. In further aspects, a plurality of implant devices can
comprise one or more implant
devices that have been solvent-treated, and one or more implant devices that
have not been solvent
treated, and/or one or more implant devices that have been solvent treated in
a different way, e.g. on
a different portion or with a different solvent or solvent solution. Various
combinations of solvent-
treatment protocols can also be used to further tailor the release profiles of
the implant devices.
When an implant device is solvent-treated, the solvent used to treat the
implant devices can contain
only solvent or can contain a polymer or another substance that will coat at
least a portion of the
implant device after the solvent-treatment. Thus, in some aspects, the implant
devices can be dip-
coated using solvent-treatment methods.
In a preferred aspect, a plurality implant devices, wherein at least two of
the implant
devices differ by release profile, are used to provide a desired cumulative
release profile. In
one specific aspect, two or more implant devices prepared from singly extruded
rods are
used together to provide a desired cumulative release profile. The plurality
of implant
devices can be used as a single mixture, for example an injectable composition
comprising
the plurality, or as separate implants, for example implants to be injected
separately.
In one aspect, a plurality of implant devices can be present in a kit. The
implant
devices of the kit can each comprise a single or multiple polymer bodies,
provided that at
least two of the implant devices in the kit exhibit a different release
profile. The kit can
18
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
comprise a suitable package or container for the implant devices. Examples
include without
limitation sterile packaging. In a further aspect, a kit can include a
prepackaged injection
device, comprising an injection device that is loaded with the implant
devices. Suitable
injection devices include without limitation syringes, trochars, and others.
The kit can also comprise a composition containing the implant devices, such
as a
pharmaceutical composition, as discussed above in reference to the bioactive
agent. Any of
those aforementioned pharmaceutical compositions can be used to contain or
provide a
medium for delivering the implant devices into a subject.
As discussed above, the impant devices are used to administer a bioactive
agent to a
subject in need thereof, for example to treat a disorder for which the
bioactive agent can
effective. The implant devices can be administered to any tissue or fluid of a
subject.
Likewise, the mode of administration can be any suitable mode, for example
subcutaneous
injection, oral administration, and the like. The number of implant devices to
be
administered will generally be selected based on the desired dosage of the
bioactive agent,
which will vary greatly depending on the disorder but can be readily
determined by one in
the pharmaceutical arts.
The implant device can be implanted in any desired subject. The subject can be
a
vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian. The
subject of the
herein disclosed methods can be, for example, a human, non-human primate,
horse, pig,
rabbit, dog, sheep, goat, cow, cat, guinea pig or rodent. The term does not
denote a
particular age or sex. Thus, adult and newborn subjects, as well as fetuses,
whether male or
female, are intended to be covered.
Bioactive agents can be administered to subjects using according to various
methodologies for which the present invention provides advantages. For
example, the
disclosed implant devices can be used in subjects that were previously treated
through dose-
titrations using oral forms of a bioactive agent in order to reach a desired
steady-state drug
pharmacokinetic level that adequately treats the disorder. One of skill in the
art can use
such prior dose-titration information to formulate an implant device or
plurality of implant
devices that provides the requisite release profile. Thus, the oral dose-
titration information,
along with known oral bioavailability values, can be used to estimate the
equivalent dose-
rate needed from implant formulations in order to reach the same (or similar)
pharmacokinetic levels. Using such a predetermined target dose level,
combinations of
multiple implants can be selected and administered to the subject in order to
achieve the
desired target dose rate level that is needed to address the form and/or
severity of their
19
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
disorder.
Alternatively, dose-titration studies can be performed using the implant
formulations
themselves (e.g. using a plurality of implant devices). According to this
aspect, initial
rounds of dosings can be performed along while monitoring plasma
pharmacokinetic levels,
whereas successive dosings can be performed using different combinations of
implants, or
combinations of portions of an implant, or both, in order to achieve the
desired steady-state
drug pharmacokinetic levels that adequately treat the disorder. Once a
suitable implant
formulation is identified that provides for the desired steady-state drug
levels, this
formulation can be used in subsequent rounds of dosing for a long-term
treatment, or for a
treatment of a chronic disorder.
EXAMPLES
The following examples are put forth so as to provide those of ordinary skill
in the
art with a complete disclosure and description of how the compounds,
compositions,
articles, devices and/or methods claimed herein are made and evaluated, and
are intended to
be purely exemplary of the invention and are not intended to limit the scope
of what the
inventors regard as their invention. Efforts have been made to ensure accuracy
with respect
to numbers (e.g., amounts, temperature, etc.), but some errors and deviations
should be
accounted for. Unless indicated otherwise, parts are parts by weight,
temperature is in C or
is at ambient temperature, and pressure is at or near atmospheric.
The formulations discuss below could be administered by a variety of methods,
including subcutaneous implantation of the implant device, or by injection the
implant
device into the subject, such as in the blood-stream of the subject. The
release profiles could
be generated by monitoring blood or plasma levels for the bioactive agent
using, for
example, liquid chromatography (LC), mass spectroscopy (MS), or combined LC-MS
methods.
Example 1: Preparation of Implant Devices
The specific implant devices discussed below were made with the bioactive
agent
Gosserelin Acetate. Each of the following formulations was blended using a
Turbula
Shaker Mixer Type T2 F. The blending was done at a setting of 0.67 for twenty
minutes for
each blend. The blends were then extruded using a Tinius Olsen Model UE-4-78
melt
plastometer. The Tinius Olsen is a solid block of steel about 80 mm in
diameter and about
160 mm high/long with a hollow core about 13 mm in diameter. The discharge of
the core
has a shoulder that allows different size dies to be used based on the desired
diameter of
extruded rod. For the Examples below, a 1.2-mm die was used, meaning that the
core of the
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
die was 1.2 mm in diameter. The main block of the Tinius Olsen has heater
bands encased
by insulation and a shroud that allows the Tinius Olsen to be heated to
desired temperatures.
A thermocouple was used to measure the temperature of the block. The control
system then
uses the thermocouple values to either turn the heater bands on or off.
Throughout the
extrusion process, the heater bands will switch off and on to maintain the
desired
temperature. The blend, approximately 2 grams in each instance, was loaded
into the
Tinitus Olsen which had been equilibrated to 90 C. A charging rod was placed
in the core
of the Tinius Olsen to compress the blend and a weight was placed on the end
of the
charging rod to aid in the compaction of the blend. The blend was
equilibrated. After an
extrusion load was placed on the charging rod, the plug was removed from the
discharge
area to begin the extrusion run. The 2-gram charge afforded segments of
extruded rod.
Formulation A
Implant Formulation A was made with bioactive agent and a poly(DL-lactide).
The
poly(DL-lactide) had an inherent viscosity of 0.26 dL/g, measured at 30 C
with 0.5gm/dL
polymer concentration in chloroform. The desired bioactive agent content in
the implant
was 5wt% Gosserelin Acetate. The extruded rod from Formulation A was cut so
that each
implant would contain 1 mg of bioactive agent.
Formulation B
Implant Formulation B was made with bioactive agent and an 85:15 poly(DL-
lactide-co-glycolide). The poly(DL-lactide-co-glycolide) had an inherent
viscosity of 0.37
dL/g, measured at 30 C with 0.5gm/dL polymer concentration in chloroform. The
desired
bioactive agent content in the implant was 5wt% Gosserelin Acetate. The
extruded rod
from Formulation B was cut so that each implant would contain 1 mg of
bioactive agent.
Formulation C
Implant Formulation C was made with bioactive agent and a poly(DL-lactide).
The
poly(DLlactide) had an inherent viscosity of 0.26 dL/g, measured at 30 C with
0.5gm/dL
polymer concentration in chloroform. The desired bioactive agent content in
the implant
was lOwt% Gosserelin Acetate. The extruded rod from Formulation C was cut to
various
lengths so that there were implants that contained 1 mg of bioactive agent,
2mg of bioactive
agent, and 4mg of bioactive agent.
Formulation D
Implant Formulation D was made with bioactive agent and an 85:15 poly(DL-
lactide-co-glycolide). The poly(DL-lactide-co-glycolide) had an inherent
viscosity of 0.37
dL/g, measured at 30 C with 0.5gm/dL polymer concentration in chloroform. The
desired
21
CA 02774495 2012-03-16
WO 2011/035013 PCT/US2010/049104
bioactive agent content in the implant was 25wt% Gosserelin Acetate. The
extruded rod
from Formulation D was cut to various lengths so that there were implants that
contained 1
mg of bioactive agent, 2 mg of bioactive agent, and 4 mg of bioactive agent.
Formulation E
Implant Formulation E was made with bioactive agent and an 85:15 poly(DL-
lactide-co-glycolide). The poly(DL-lactide-co-glycolide) had an inherent
viscosity of 0.37
dL/g, measured at 30 C with 0.5gm/dL polymer concentration in chloroform. The
desired
bioactive agent content in the implant was lOwt% Gosserelin Acetate. The
extruded rod
from Formulation E was cut to various lengths so that there were implants that
contained 1
mg of bioactive agent, 2 mg of bioactive agent, and 4 mg of bioactive agent.
Formulation F
Implant Formulation F was made with bioactive agent and a poly(DL-lactide).
The
poly(DL-lactide) had an inherent viscosity of 0.26 dL/g, measured at 30 C
with 0.5gm/dL
polymer concentration in chloroform. The desired bioactive agent content in
the implant
was 25wt% Gosserelin Acetate. The extruded rod from Formulation F was cut to
various
lengths so that there were implants that contained 1 mg of bioactive agent, 2
mg of bioactive
agent, and 4 mg of bioactive agent.
Example 2: Same Loading with Different Polymer
To achieve a desired release profile of a bioactive agent, the polymer can be
changed. An example of this is comparing Formulations D and F as described
above. The
release profiles of Formulations D and F are shown in Fig. 3.
Example 3: Different Loading with Same Polymer
Another approach to achieving a desired release profile is to change to
loading of
bioactive agent in the implant. An example of this is comparing Formulations C
and F as
described above. The release profiles of Formulations C and F are shown in
Fig. 4.
Example 3: Use of Multiple Implant Devices
Different formulations can be used in varying quantities to form a dose of
bioactive
agent administered at one time (FIGs. 5, 6). FIG. 5 shows the release of
Formulation C and
Formulation F. The others shown on the graph in FIG. 5 all have 4 mg bioactive
agent, but
were generated by combining implants of different formulations. Figure 6 uses
Formulation
D and Formulation F as the basis for comparison with different combinations.
As evident in
these graphs, the ability to manipulate release kinetics is greatly enhanced
through the use
of multiple implants.
22
CA 02774495 2012-03-16
WO 2011/035013
PCT/US2010/049104
Example 4 (Prophetic): Tailoring Dose
A set of implant formulations can be prepared that, individually, provide for
different average daily release rates over approximately a 4 week period of
time.
Formulations 1, 2, and 3 provide for daily release rates of approximately 2,
4, and 8
micrograms drug per day for the 4-week period (respectively).
Patient 1 is known from prior experience (based on previous dose-titrations
using
oral versions of the drug) to require treatment with this drug at a level of
approximately 8
micrograms drug per day to treat his particular form and severity of disease.
Patient 2 is known (based on similar prior experience) to require treatment at
a level
of 12 micrograms drug per day to treat his particular form and severity of
disease.
Patient 3 is known (based on similar prior experience) to require treatment at
a level
of 14 micrograms drug per day to treat his particular form and severity of
disease.
Using the the present invention, Patient 1 could therefore be treated by
administration of one dose of Formulation 3. Patient 2 could therefore be
treated by
administration of one dose of Formulation 2 and one dose of Formulation 3.
Patient 3 could
therefore be treated by administration of one dose of Formulation 1, one dose
of
Formulation 2 and one dose of Formulation 3. Formulations 1-3 can be provided
by using
combinations of implants, or implants having different polymer bodies or
sections, as in
Fig. 1B, 1C, Figs. 2A-D, or both, as discussed above.
Various modifications and variations can be made to the compounds, composites,
kits, articles, devices, compositions, and methods described herein. Other
aspects of the the
compounds, composites, kits, articles, devices, compositions, and methods
described herein
will be apparent from consideration of the specification and practice of the
the compounds,
composites, kits, articles, devices, compositions, and methods disclosed
herein. It is
intended that the specification and examples be considered as exemplary.
23
